BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

By: via Benzinga
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.